Showing 31-40 of 5234 results for "".
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of psoriatic disease. Research funded by NPF g…
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of atopic derm…
- 2014 AAD Election Resultshttps://practicaldermatology.com/news/20140424-2014_aad_election_results/2459257/Election ballots were sent to 13,783 eligible voting members of the American Academy of Dermatology (AAD). A total of 4,178 (30.31%) members returned ballots, according the AAD. Newly elected officers and directors will officially take office at the conclusion of the 2015 An…
- Pivotal Phase 3 Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne Meet All Efficacy Endpointshttps://practicaldermatology.com/news/pivotal-phase-3-trials-of-trifarotene-in-patients-with-moderate-facial-and-truncal-acne-meet-all-efficacy-endpoints-2/2460056/Results from the pivotal Phase 3 PERFECT 1 and PERFECT 2 clinical trials of once-daily trifarotene 50 µg/g cream in patients with moderate acne on the face and trunk, published in the June issue of Journal of the American Academy of Dermatology, met all primary and secondary efficacy endpoints. Tri…
- Ruxolitinib cream 1.5% Demonstrates Tolerability, Safety Over 52 Weeks in Childrenhttps://practicaldermatology.com/news/ruxolitinib-cream-15-demonstrates-tolerability-safety-over-52-weeks-children/2467044/Ruxolitinib cream 1.5% demonstrated consistently good tolerability and safety over 52 weeks in children 2 to 11 years old with extensive moderate-to-severe atopic dermatitis (AD) in a study presented this month at the Revolutionizing Atopic Dermatitis (RAD) Conference in Chicago, Illinois. Eight-we…
- Alastin Skincare Launches Trihex Transition Duo at ASDShttps://practicaldermatology.com/news/alastin-skincare-launches-trihex-transition-duo-at-asds/2458027/ALASTIN Skincare®, Inc. is launching the TriHex Transition Duo at the American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago. The TriHex Transition Duo includes a full-size Regenerating Skin Nectar for use pre- and post-procedure and a transition-size Restorative Skin Complex f…
- Valeant Announces Nominees For Election To Board Of Directorshttps://practicaldermatology.com/news/valeant-announces-nominees-for-election-to-board-of-directors/2458585/Valeant Pharmaceuticals International, Inc. announced the nominees for election to its Board of Directors at the 2016 Annual Meeting of Shareholders on June 14, 2016. As previoulsy announced, Joseph C. Papa has been named Valeant's Chairman and Chief Executive Officer. Mr. Papa has been nominated f…
- Allergan Acquires Topokine Therapeuticshttps://practicaldermatology.com/news/allergan-acquires-topokine-therapeutics/2458596/Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development a…
- CMS Assigns Q-code to Fish Skin Technology, Kerecis Reportshttps://practicaldermatology.com/news/20141113-cms_assigns_q-code_to_fish_skin_technology_kerecis_reports/2459065/The new Omega3 tissue-regeneration material from Kerecis Limited—dubbed fish skin—has received a "Q" code from the Centers for Medicare and Medicaid Services (CMS). Kerecis Omega3 Wound, indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds, has …
- Mirvaso Now Available in the UKhttps://practicaldermatology.com/news/20140417-mirvaso_now_available_in_the_uk/2459269/Mirvaso (brimonidine) 3mg/g gel, an alpha-2 adrenergic agonist indicated for the symptomatic treatment facial erythema associated with rosacea in adult patients, is now available in the UK. The active ingredient, brimonidine, restricts excessive blood flow to the upper layers of the skin. The topi…